{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T10:22:45Z","timestamp":1778840565973,"version":"3.51.4"},"reference-count":26,"publisher":"Japanese Society of Internal Medicine","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2015]]},"DOI":"10.2169\/internalmedicine.54.3103","type":"journal-article","created":{"date-parts":[[2015,4,30]],"date-time":"2015-04-30T22:05:18Z","timestamp":1430431518000},"page":"1125-1130","source":"Crossref","is-referenced-by-count":10,"title":["Fatal Complication of &lt;i&gt;Legionella pneumophila&lt;\/i&gt; Pneumonia in a Tocilizumab-treated Rheumatoid Arthritis Patient"],"prefix":"10.2169","volume":"54","author":[{"given":"Yoshiyuki","family":"Arinuma","sequence":"first","affiliation":[{"name":"Department of Rheumatology, National Hospital Organization Sagamihara National Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichi","family":"Nogi","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, National Hospital Organization Sagamihara National Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichi","family":"Ishikawa","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, National Hospital Organization Sagamihara National Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisanori","family":"Nakayama","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, National Hospital Organization Sagamihara National Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Hashimoto","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, National Hospital Organization Sagamihara National Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiko","family":"Komiya","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, National Hospital Organization Sagamihara National Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Minoguchi","sequence":"additional","affiliation":[{"name":"Department of Allergology and Respiratory Medicine, National Hospital Organization Sagamihara National Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayako","family":"Horita","sequence":"additional","affiliation":[{"name":"Department of Pathology, National Hospital Organization Sagamihara National Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ikuo","family":"Saito","sequence":"additional","affiliation":[{"name":"Department of Pathology, National Hospital Organization Sagamihara National Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihiro","family":"Matsui","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, National Hospital Organization Sagamihara National Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeto","family":"Tohma","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Clinical Research Center for Allergy and Rheumatology, National Hospital Organization Sagamihara National Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Smolen JS, Aletaha D, Bijlsma JW, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 69: 631-637, 2010.","DOI":"10.1136\/ard.2009.123919"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Aletaha D, Neogi T, Silman AJ, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 69: 1580-1588, 2010.","DOI":"10.1136\/ard.2010.138461"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Felson DT, Smolen JS, Wells G, et al. American College of Rheumatology\/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis 70: 404-413, 2011.","DOI":"10.1136\/ard.2011.149765"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Salliot C, Finckh A, Katchamart W, et al. Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysis. Ann Rheum Dis 70: 266-271, 2011.","DOI":"10.1136\/ard.2010.132134"},{"key":"5","unstructured":"5. Smolen JS, Landew&eacute; R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 69: 964-975, 2010."},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Nishimoto N, Kishimoto T. Interleukin 6: from bench to bedside. Nat Clin Pract Rheumatol 2: 619-626, 2006.","DOI":"10.1038\/ncprheum0338"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Singh JA, Wells GA, Christensen R, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 16: CD008794, 2011.","DOI":"10.1002\/14651858.CD008794.pub2"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Campbell L, Chen C, Bhagat SS, et al. Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials. Rheumatology 50: 552-562, 2011.","DOI":"10.1093\/rheumatology\/keq343"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Koike T, Harigai M, Inokuma S, et al. Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients. Ann Rheum Dis 70: 2148-2151, 2011.","DOI":"10.1136\/ard.2011.151092"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Hoshi D, Nakajima A, Inoue E, et al. Incidence of serious respiratory infections in patients with rheumatoid arthritis treated with tocilizumab. Mod Rheumatol 22: 122-127, 2012.","DOI":"10.3109\/s10165-011-0488-6"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Wondergem MJ, Voskuyl AE, van Agtmael MA. A case of legionellosis during treatment with a TNFalpha antagonist. Scand J Infect Dis 36: 310-311, 2004.","DOI":"10.1080\/00365540410019598"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Li Gobbi F, Benucci M, Del Rosso A. Pneumonitis caused by Legionella pneumoniae in a patient with rheumatoid arthritis treated with anti-TNF-alpha therapy (infliximab). J Clin Rheumatol 11: 119-120, 2005.","DOI":"10.1097\/01.rhu.0000158527.20518.30"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Tubach F, Ravaud P, Salmon-C&eacute;ron D, et al. Emergence of <i>Legionella pneumophila<\/i> pneumonia in patients receiving tumor necrosis factor-alpha antagonists. Clin Infect Dis 43: e95-e100, 2006.","DOI":"10.1086\/508538"},{"key":"14","unstructured":"14. Jinno S, Pulido S, Pien BC. First reported United States case of <i>Legionella pneumophila<\/i> serogroup 1 pneumonia in a patient receiving anti-tumor necrosis factor-alpha therapy. Hawaii Med J 68: 109-112, 2009."},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Prevoo ML, van't Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38: 44-48, 1995.","DOI":"10.1002\/art.1780380107"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Aletaha D, Nell VP, Stamm T, et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther 7: R796-R806, 2005.","DOI":"10.1186\/ar1740"},{"key":"17","unstructured":"17. Matsui T, Ohsumi K, Ozawa N, et al. CD64 on neutrophils is a sensitive and specific marker for detection of infection in patients with rheumatoid arthritis. J Rheumatol 33: 2416-2424, 2006."},{"key":"18","unstructured":"18. ARDS Definition Task Force, Ranieri VM, Rubenfeld GD, et al. Acute respiratory distress syndrome: the Berlin Definition. JAMA 307: 2526-2533, 2012."},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Fujiwara H, Nishimoto N, Hamano Y, et al. Masked early symptoms of pneumonia in patients with rheumatoid arthritis during tocilizumab treatment: a report of two cases. Mod Rheumatol 19: 64-68, 2009.","DOI":"10.3109\/s10165-008-0111-7"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Men&eacute;ndez R, Sahuquillo-Arce JM, Reyes S, et al. Cytokine activation patterns and biomarkers are influenced by microorganisms in community-acquired pneumonia. Chest 141: 1537-1545, 2012.","DOI":"10.1378\/chest.11-1446"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Chang B, Amemura-Maekawa J, Kura F, et al. Expression of IL-6 and TNF-alpha in human alveolar epithelial cells is induced by invading, but not by adhering, Legionella pneumophila. Microb Pathog 37: 295-302, 2004.","DOI":"10.1016\/j.micpath.2004.10.002"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Lang VR, Englbrecht M, Rech J, et al. Risk of infections in rheumatoid arthritis patients treated with tocilizumab. Rheumatology 51: 852-857, 2012.","DOI":"10.1093\/rheumatology\/ker223"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Matsui T, Komiya A, Shimada K, et al. Neutrophil CD64 as a marker of infection in patients treated with tocilizumab. Mod Rheumatol 19: 696-697, 2009.","DOI":"10.3109\/s10165-009-0223-8"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Tang BM, Eslick GD, Craig JC, et al. Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: systematic review and meta-analysis. Lancet Infect Dis 7: 210-217, 2007.","DOI":"10.1016\/S1473-3099(07)70052-X"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Franzin L, Cabodi D. Legionella pneumonia and serum procalcitonin. Curr Microbiol 50: 43-46, 2005.","DOI":"10.1007\/s00284-004-4360-1"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Haeuptle J, Zaborsky R, Fiumefreddo R, et al. Prognostic value of procalcitonin in Legionella pneumonia. Eur J Clin Microbiol Infect Dis 28: 55-60, 2009.","DOI":"10.1007\/s10096-008-0592-5"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","deposited":{"date-parts":[[2019,8,24]],"date-time":"2019-08-24T10:59:23Z","timestamp":1566644363000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/54\/9\/54_54.3103\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"references-count":26,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.54.3103","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015]]}}}